Characteristics of patients treated with calcipotriol
| n | 8 |
| Median age in years (range) | 43 (29-52) |
| Epidemic KS | 7 (88%) |
| Classic KS | 1 (12.5%) |
| Prior opportunistic infection | 3 (38%) |
| Median CD4+ lymphocytes/mm3 (range) | 59 (20-421) |
| B symptoms | 1 (12.5%) |
| KS extent | |
| > 10 lesions | 4 (50%) |
| < 10 lesions | 4 (50%) |
| Lymphedema | 2 (25%) |
| Prior therapy for KS | |
| None | 2 (25%) |
| Local only | 4 (50%) |
| Systemic chemotherapy | 2 (25%) |
| n | 8 |
| Median age in years (range) | 43 (29-52) |
| Epidemic KS | 7 (88%) |
| Classic KS | 1 (12.5%) |
| Prior opportunistic infection | 3 (38%) |
| Median CD4+ lymphocytes/mm3 (range) | 59 (20-421) |
| B symptoms | 1 (12.5%) |
| KS extent | |
| > 10 lesions | 4 (50%) |
| < 10 lesions | 4 (50%) |
| Lymphedema | 2 (25%) |
| Prior therapy for KS | |
| None | 2 (25%) |
| Local only | 4 (50%) |
| Systemic chemotherapy | 2 (25%) |
KS indicates Kaposi sarcoma.